Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-07

AUTHORS

M McKibbin, H Devonport, R Gale, M Gavin, A Lotery, S Mahmood, P J Patel, A Ross, S Sivaprasad, J Talks, G Walters

ABSTRACT

This paper provides expert recommendations on administration of aflibercept in wet age-related macular degeneration (AMD) after Year 1 (Y1), based on a roundtable discussion held in London, UK in November 2014. The goals of treatment after Y1 are to maintain visual and anatomical gains whilst minimising treatment burden and using resources effectively. The treatment decision should be made at the seventh injection visit (assuming the label has been followed) in Y1, and three approaches are proposed: (a) eyes with active disease on imaging/examination but with stable visual acuity (VA) at the end of Y1 should continue with fixed 8-weekly dosing; (b) eyes with inactive disease on imaging/examination and stable VA should be managed using a 'treat and extend' (T&E) regimen. T&E involves treating and then extending the interval until the next treatment, by 2-week intervals, to a maximum of 12 weeks, provided the disease remains inactive. If there is new evidence of disease activity, treatment is administered and the interval to the next treatment shortened; and (c) if there has been no disease activity for ≥3 consecutive visits, a trial of monitoring without treatment may be appropriate, initiated at the end of Y1 or at any time during Y2. Where possible, VA testing, OCT imaging and injection should be performed at the same visit. The second eye should be monitored to detect fellow eye involvement. In bilateral disease, the re-treatment interval should be driven by the better-seeing eye or, if the VA is similar, the eye with the more active disease. More... »

PAGES

s1

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/eye.2015.77

DOI

http://dx.doi.org/10.1038/eye.2015.77

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017349485

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26156564


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1113", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Ophthalmology and Optometry", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intravitreal Injections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Vascular Endothelial Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Fusion Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Visual Acuity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Wet Macular Degeneration", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "St James's University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.443984.6", 
          "name": [
            "Ophthalmology Department, St James's University Hospital, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKibbin", 
        "givenName": "M", 
        "id": "sg:person.01132765043.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132765043.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bradford Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.418447.a", 
          "name": [
            "Ophthalmology Department, Bradford Royal Infirmary, Bradford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Devonport", 
        "givenName": "H", 
        "id": "sg:person.0775023771.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775023771.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "York Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417375.3", 
          "name": [
            "Ophthalmology Department, The York Hospital, York, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gale", 
        "givenName": "R", 
        "id": "sg:person.0652620226.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652620226.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "NHS Greater Glasgow and Clyde", 
          "id": "https://www.grid.ac/institutes/grid.413301.4", 
          "name": [
            "Ophthalmology Department, NHS Greater Glasgow and Clyde, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gavin", 
        "givenName": "M", 
        "id": "sg:person.0620406757.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620406757.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Southampton General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.123047.3", 
          "name": [
            "Southampton General Hospital, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lotery", 
        "givenName": "A", 
        "id": "sg:person.01213427467.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213427467.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK", 
            "Centre for Ophthalmology & Vision Sciences, Institute of Human Development, University of Manchester, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahmood", 
        "givenName": "S", 
        "id": "sg:person.0713701516.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713701516.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Health Research", 
          "id": "https://www.grid.ac/institutes/grid.451056.3", 
          "name": [
            "NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "P J", 
        "id": "sg:person.01060311107.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060311107.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol Eye Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415175.3", 
          "name": [
            "Bristol Eye Hospital, Bristol, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ross", 
        "givenName": "A", 
        "id": "sg:person.01117525654.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117525654.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Health Research", 
          "id": "https://www.grid.ac/institutes/grid.451056.3", 
          "name": [
            "NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sivaprasad", 
        "givenName": "S", 
        "id": "sg:person.0620470737.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620470737.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Victoria Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.419334.8", 
          "name": [
            "Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Talks", 
        "givenName": "J", 
        "id": "sg:person.01117041545.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117041545.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Harrogate District Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413714.4", 
          "name": [
            "Department of Ophthalmology, Harrogate District Hospital, Harrogate, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walters", 
        "givenName": "G", 
        "id": "sg:person.01150223000.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150223000.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ophtha.2013.03.046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005909207"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archopht.1993.01090090041018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014392640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmicm1005605", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015789727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ophtha.2013.11.031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016383864"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1102673", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018732383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ophtha.2012.03.053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018935436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ophtha.2012.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025409499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ophtha.2013.08.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034402795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(13)61501-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043271928"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bjophthalmol-2011-301109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051486550"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/9781420019865-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1088305538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/b-002-26638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1096900424"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-07", 
    "datePublishedReg": "2015-07-01", 
    "description": "This paper provides expert recommendations on administration of aflibercept in wet age-related macular degeneration (AMD) after Year 1 (Y1), based on a roundtable discussion held in London, UK in November 2014. The goals of treatment after Y1 are to maintain visual and anatomical gains whilst minimising treatment burden and using resources effectively. The treatment decision should be made at the seventh injection visit (assuming the label has been followed) in Y1, and three approaches are proposed: (a) eyes with active disease on imaging/examination but with stable visual acuity (VA) at the end of Y1 should continue with fixed 8-weekly dosing; (b) eyes with inactive disease on imaging/examination and stable VA should be managed using a 'treat and extend' (T&E) regimen. T&E involves treating and then extending the interval until the next treatment, by 2-week intervals, to a maximum of 12 weeks, provided the disease remains inactive. If there is new evidence of disease activity, treatment is administered and the interval to the next treatment shortened; and (c) if there has been no disease activity for \u22653 consecutive visits, a trial of monitoring without treatment may be appropriate, initiated at the end of Y1 or at any time during Y2. Where possible, VA testing, OCT imaging and injection should be performed at the same visit. The second eye should be monitored to detect fellow eye involvement. In bilateral disease, the re-treatment interval should be driven by the better-seeing eye or, if the VA is similar, the eye with the more active disease. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/eye.2015.77", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097007", 
        "issn": [
          "0950-222X", 
          "1476-5454"
        ], 
        "name": "Eye", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "S1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "name": "Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel", 
    "pagination": "s1", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "52a8dccdac17234cb15267b24b9e6f65648fce048fe8f39063bf829977cf975d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26156564"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8703986"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/eye.2015.77"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017349485"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/eye.2015.77", 
      "https://app.dimensions.ai/details/publication/pub.1017349485"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000549.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/eye201577"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/eye.2015.77'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/eye.2015.77'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/eye.2015.77'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/eye.2015.77'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      21 PREDICATES      49 URIs      29 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/eye.2015.77 schema:about N12a986f448d04ec8be55df1f5448af61
2 N209279c0301c443ea08f84f94e919319
3 N3028ac9598344d79b4f0e2d5ee3780c1
4 N3b00211d53464e538e5972985a92422d
5 N424de2fa5b804bec9a4c85f4e210aa5b
6 N6596ab62dc734889933dc022eecb5b98
7 Nd462a7587d164e29a918051f1f741095
8 Nd9a2547d79a64926940a3b6dcd93d4af
9 anzsrc-for:11
10 anzsrc-for:1113
11 schema:author Nc75c4312e4b84fe588a98c8d5a6cf36b
12 schema:citation https://doi.org/10.1001/archopht.1993.01090090041018
13 https://doi.org/10.1016/j.ophtha.2012.03.053
14 https://doi.org/10.1016/j.ophtha.2012.09.006
15 https://doi.org/10.1016/j.ophtha.2013.03.046
16 https://doi.org/10.1016/j.ophtha.2013.08.011
17 https://doi.org/10.1016/j.ophtha.2013.11.031
18 https://doi.org/10.1016/s0140-6736(13)61501-9
19 https://doi.org/10.1055/b-002-26638
20 https://doi.org/10.1056/nejmicm1005605
21 https://doi.org/10.1056/nejmoa1102673
22 https://doi.org/10.1136/bjophthalmol-2011-301109
23 https://doi.org/10.3109/9781420019865-9
24 schema:datePublished 2015-07
25 schema:datePublishedReg 2015-07-01
26 schema:description This paper provides expert recommendations on administration of aflibercept in wet age-related macular degeneration (AMD) after Year 1 (Y1), based on a roundtable discussion held in London, UK in November 2014. The goals of treatment after Y1 are to maintain visual and anatomical gains whilst minimising treatment burden and using resources effectively. The treatment decision should be made at the seventh injection visit (assuming the label has been followed) in Y1, and three approaches are proposed: (a) eyes with active disease on imaging/examination but with stable visual acuity (VA) at the end of Y1 should continue with fixed 8-weekly dosing; (b) eyes with inactive disease on imaging/examination and stable VA should be managed using a 'treat and extend' (T&E) regimen. T&E involves treating and then extending the interval until the next treatment, by 2-week intervals, to a maximum of 12 weeks, provided the disease remains inactive. If there is new evidence of disease activity, treatment is administered and the interval to the next treatment shortened; and (c) if there has been no disease activity for ≥3 consecutive visits, a trial of monitoring without treatment may be appropriate, initiated at the end of Y1 or at any time during Y2. Where possible, VA testing, OCT imaging and injection should be performed at the same visit. The second eye should be monitored to detect fellow eye involvement. In bilateral disease, the re-treatment interval should be driven by the better-seeing eye or, if the VA is similar, the eye with the more active disease.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf Nb53a8fc27d064b52af41971b6a4f63db
31 Ndae49c141e7b419c942226566fbc93dd
32 sg:journal.1097007
33 schema:name Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
34 schema:pagination s1
35 schema:productId N40c6e4c016f6422eac2e501a96ba4ee2
36 N4b83c26de8024fefaade1603fd56489f
37 N6b6fb2b207c2433495445f90a480d6f0
38 Ne5ed2956437d4d5ca27fd6da83ac4303
39 Nfe63280dfb6e428e8968234445bf06fc
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017349485
41 https://doi.org/10.1038/eye.2015.77
42 schema:sdDatePublished 2019-04-10T22:39
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N033bcedfe4e44342a73b75067fff7cc9
45 schema:url https://www.nature.com/articles/eye201577
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N033bcedfe4e44342a73b75067fff7cc9 schema:name Springer Nature - SN SciGraph project
50 rdf:type schema:Organization
51 N12a986f448d04ec8be55df1f5448af61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
52 schema:name Visual Acuity
53 rdf:type schema:DefinedTerm
54 N1a08a4bc2bb840feb4e74c28a432ceb5 rdf:first sg:person.0620406757.62
55 rdf:rest Nf1886764f0c0434cb1131d470e76fce5
56 N209279c0301c443ea08f84f94e919319 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Wet Macular Degeneration
58 rdf:type schema:DefinedTerm
59 N3028ac9598344d79b4f0e2d5ee3780c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Angiogenesis Inhibitors
61 rdf:type schema:DefinedTerm
62 N3b00211d53464e538e5972985a92422d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Recombinant Fusion Proteins
64 rdf:type schema:DefinedTerm
65 N40c6e4c016f6422eac2e501a96ba4ee2 schema:name doi
66 schema:value 10.1038/eye.2015.77
67 rdf:type schema:PropertyValue
68 N424de2fa5b804bec9a4c85f4e210aa5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Humans
70 rdf:type schema:DefinedTerm
71 N45150264a8d0475b99957fac355f38a6 rdf:first sg:person.01150223000.99
72 rdf:rest rdf:nil
73 N4b83c26de8024fefaade1603fd56489f schema:name dimensions_id
74 schema:value pub.1017349485
75 rdf:type schema:PropertyValue
76 N5230d82a33e9493ea88e4a556d5b30d9 rdf:first sg:person.0652620226.17
77 rdf:rest N1a08a4bc2bb840feb4e74c28a432ceb5
78 N6596ab62dc734889933dc022eecb5b98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Receptors, Vascular Endothelial Growth Factor
80 rdf:type schema:DefinedTerm
81 N6b6fb2b207c2433495445f90a480d6f0 schema:name nlm_unique_id
82 schema:value 8703986
83 rdf:type schema:PropertyValue
84 N7caca24136494225a9e345c84716e4a6 rdf:first sg:person.01117525654.01
85 rdf:rest Nbe8c26256c5b4417ae87c1dd811b8ae2
86 Nb53a8fc27d064b52af41971b6a4f63db schema:issueNumber S1
87 rdf:type schema:PublicationIssue
88 Nbe8c26256c5b4417ae87c1dd811b8ae2 rdf:first sg:person.0620470737.39
89 rdf:rest Nc37cdf9f175546809235f17532872dba
90 Nc37cdf9f175546809235f17532872dba rdf:first sg:person.01117041545.71
91 rdf:rest N45150264a8d0475b99957fac355f38a6
92 Nc75c4312e4b84fe588a98c8d5a6cf36b rdf:first sg:person.01132765043.25
93 rdf:rest Nf3f8d62afae94b5293d93d4ccbbf7ff2
94 Nd462a7587d164e29a918051f1f741095 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Clinical Trials as Topic
96 rdf:type schema:DefinedTerm
97 Nd9a2547d79a64926940a3b6dcd93d4af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Intravitreal Injections
99 rdf:type schema:DefinedTerm
100 Ndae49c141e7b419c942226566fbc93dd schema:volumeNumber 29
101 rdf:type schema:PublicationVolume
102 Ne5ed2956437d4d5ca27fd6da83ac4303 schema:name readcube_id
103 schema:value 52a8dccdac17234cb15267b24b9e6f65648fce048fe8f39063bf829977cf975d
104 rdf:type schema:PropertyValue
105 Neb37f30139cf449a944594142c83a982 rdf:first sg:person.0713701516.16
106 rdf:rest Nf9bbd5360fba44ed9f70ff4b12f3f453
107 Nf1886764f0c0434cb1131d470e76fce5 rdf:first sg:person.01213427467.35
108 rdf:rest Neb37f30139cf449a944594142c83a982
109 Nf3f8d62afae94b5293d93d4ccbbf7ff2 rdf:first sg:person.0775023771.36
110 rdf:rest N5230d82a33e9493ea88e4a556d5b30d9
111 Nf9bbd5360fba44ed9f70ff4b12f3f453 rdf:first sg:person.01060311107.03
112 rdf:rest N7caca24136494225a9e345c84716e4a6
113 Nfe63280dfb6e428e8968234445bf06fc schema:name pubmed_id
114 schema:value 26156564
115 rdf:type schema:PropertyValue
116 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
117 schema:name Medical and Health Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:1113 schema:inDefinedTermSet anzsrc-for:
120 schema:name Ophthalmology and Optometry
121 rdf:type schema:DefinedTerm
122 sg:journal.1097007 schema:issn 0950-222X
123 1476-5454
124 schema:name Eye
125 rdf:type schema:Periodical
126 sg:person.01060311107.03 schema:affiliation https://www.grid.ac/institutes/grid.451056.3
127 schema:familyName Patel
128 schema:givenName P J
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060311107.03
130 rdf:type schema:Person
131 sg:person.01117041545.71 schema:affiliation https://www.grid.ac/institutes/grid.419334.8
132 schema:familyName Talks
133 schema:givenName J
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117041545.71
135 rdf:type schema:Person
136 sg:person.01117525654.01 schema:affiliation https://www.grid.ac/institutes/grid.415175.3
137 schema:familyName Ross
138 schema:givenName A
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117525654.01
140 rdf:type schema:Person
141 sg:person.01132765043.25 schema:affiliation https://www.grid.ac/institutes/grid.443984.6
142 schema:familyName McKibbin
143 schema:givenName M
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132765043.25
145 rdf:type schema:Person
146 sg:person.01150223000.99 schema:affiliation https://www.grid.ac/institutes/grid.413714.4
147 schema:familyName Walters
148 schema:givenName G
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150223000.99
150 rdf:type schema:Person
151 sg:person.01213427467.35 schema:affiliation https://www.grid.ac/institutes/grid.123047.3
152 schema:familyName Lotery
153 schema:givenName A
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213427467.35
155 rdf:type schema:Person
156 sg:person.0620406757.62 schema:affiliation https://www.grid.ac/institutes/grid.413301.4
157 schema:familyName Gavin
158 schema:givenName M
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620406757.62
160 rdf:type schema:Person
161 sg:person.0620470737.39 schema:affiliation https://www.grid.ac/institutes/grid.451056.3
162 schema:familyName Sivaprasad
163 schema:givenName S
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620470737.39
165 rdf:type schema:Person
166 sg:person.0652620226.17 schema:affiliation https://www.grid.ac/institutes/grid.417375.3
167 schema:familyName Gale
168 schema:givenName R
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652620226.17
170 rdf:type schema:Person
171 sg:person.0713701516.16 schema:affiliation https://www.grid.ac/institutes/grid.5379.8
172 schema:familyName Mahmood
173 schema:givenName S
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713701516.16
175 rdf:type schema:Person
176 sg:person.0775023771.36 schema:affiliation https://www.grid.ac/institutes/grid.418447.a
177 schema:familyName Devonport
178 schema:givenName H
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775023771.36
180 rdf:type schema:Person
181 https://doi.org/10.1001/archopht.1993.01090090041018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014392640
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.ophtha.2012.03.053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018935436
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/j.ophtha.2012.09.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025409499
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/j.ophtha.2013.03.046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005909207
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/j.ophtha.2013.08.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034402795
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.ophtha.2013.11.031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016383864
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0140-6736(13)61501-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043271928
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1055/b-002-26638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1096900424
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejmicm1005605 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015789727
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1056/nejmoa1102673 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018732383
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1136/bjophthalmol-2011-301109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051486550
202 rdf:type schema:CreativeWork
203 https://doi.org/10.3109/9781420019865-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1088305538
204 rdf:type schema:CreativeWork
205 https://www.grid.ac/institutes/grid.123047.3 schema:alternateName Southampton General Hospital
206 schema:name Southampton General Hospital, Southampton, UK
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.413301.4 schema:alternateName NHS Greater Glasgow and Clyde
209 schema:name Ophthalmology Department, NHS Greater Glasgow and Clyde, UK
210 rdf:type schema:Organization
211 https://www.grid.ac/institutes/grid.413714.4 schema:alternateName Harrogate District Hospital
212 schema:name Department of Ophthalmology, Harrogate District Hospital, Harrogate, UK
213 rdf:type schema:Organization
214 https://www.grid.ac/institutes/grid.415175.3 schema:alternateName Bristol Eye Hospital
215 schema:name Bristol Eye Hospital, Bristol, UK
216 rdf:type schema:Organization
217 https://www.grid.ac/institutes/grid.417375.3 schema:alternateName York Hospital
218 schema:name Ophthalmology Department, The York Hospital, York, UK
219 rdf:type schema:Organization
220 https://www.grid.ac/institutes/grid.418447.a schema:alternateName Bradford Royal Infirmary
221 schema:name Ophthalmology Department, Bradford Royal Infirmary, Bradford, UK
222 rdf:type schema:Organization
223 https://www.grid.ac/institutes/grid.419334.8 schema:alternateName Royal Victoria Infirmary
224 schema:name Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK
225 rdf:type schema:Organization
226 https://www.grid.ac/institutes/grid.443984.6 schema:alternateName St James's University Hospital
227 schema:name Ophthalmology Department, St James's University Hospital, Leeds, UK
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.451056.3 schema:alternateName National Institute for Health Research
230 schema:name NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.5379.8 schema:alternateName University of Manchester
233 schema:name Centre for Ophthalmology & Vision Sciences, Institute of Human Development, University of Manchester, Manchester, UK
234 Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...